期刊文献+

重度卵巢过度刺激综合征患者的门诊管理 被引量:2

下载PDF
导出
摘要 卵巢过度刺激综合征(ovarian hyperstimulation syndrome,OHSS)是辅助生殖技术实施过程中常见的,以毛细血管通透性增加、体液外渗、血液浓缩为主要病理变化的医源性自限性疾病.轻度和部分中度OHSS患者病情具有自限性,可不予干预.重度OHSS患者会出现大量胸腹腔积液,脏器血栓形成、电解质及酸碱平衡紊乱、肝肾功能衰竭,严重时可导致死亡.重度OHSS的发生率为0.1%~2.0%[1].普遍认为重度OHSS患者应入院治疗以便密切监测和及早发现严重并发症,但目前也有研究表明对部分重度OHSS患者采取门诊治疗是安全、有效、具有成本效益的,并且由于不需要住院,患者也更易于接受[2-7].笔者就重度OHSS患者的门诊管理进行阐述.
出处 《西南国防医药》 CAS 2020年第6期574-576,共3页 Medical Journal of National Defending Forces in Southwest China
基金 四川省卫生健康委员会科研基金(18PJ052)。
  • 相关文献

参考文献1

二级参考文献58

  • 1Papanikolaou EG, Pozzobon C, Kolibianakis EM, et al. Incidence and prediction of ovarian hyperstimulation syn- drome in women undergoing gonadoWopin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril, 2006, 85 (1):112-20.
  • 2Busso C, M, Garcia-Velasoa JA, etal. The non-ergot derived dopamine agonist quinagolide in pre- vention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-ennm)lled trial. Hum Reprod, 2010, 25(4):995-1004.
  • 3Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril, 2010, 94(2):389-400.
  • 4Al-Inany HG, Youssef MA, Aboulghar M, et al. Gonadotro- phin-releasing hormone antagonists for assisted reproduc- tive technology. Cochrane Database Syst Rev, 2011(5): CD001750.
  • 5Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperslsulafion syndrome (OHSS): the need for individualized not standardized treatment. Reprod Biol Endoerinol, 2012, 10:32.
  • 6Tsoumpou I, Muglu J, G-elbaya TA, et al. Symposium: Update on prediction and management of OHSS. Optimal dose of HCG for final ooeyte maturation in IVF cycles: absence of evidence? Reprod Biomed Online, 2009, 19(1):52-8.
  • 7Lainas TG, Sfontouris IA, Zorzovilis IZ, et al. Management of severe early ovarian hyperstimulation syndrome by re- initiation of CmRH antagonist. Reprod Biomed Online, 2007, 15(4):408-12.
  • 8Lainas TG, Sfontouris IA, Zorzovilis IZ, et al. Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol. Reprod Biomed Online, 2009, 18( 1): 15-20.
  • 9Wada I, Matson PL, Home G, et al. Is continuation of a gouadotrophin-releasing hormone agonist (CmRHa) necessary for women at risk of developing the ovarian hyper-stimulation syndrome? Hum Reprod, 1992, 7(8): 1090-3.
  • 10Endo T, Hounma H, Hayashi T, et al. Continuation of GnRH agonist administration for 1 week, after hCG injection, pre- vents ovarian hyperstimtdation syndrome following elective cryopreservation ofaU pronucleate embryos. Hum Reprod, 2002, 17(10):2548-51.

共引文献80

同被引文献31

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部